施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

盘前交易 05-28 05:19:36 EDT

57.52

-0.51

-0.88%

盘前57.75

+0.23+0.40%

04:32 EDT

最高58.80	最低57.13	成交量934.80万
今开58.03	昨收58.03	日振幅2.88%
总市值1,171亿	流通市值1,169亿	总股本20.36亿
成交额5.41亿	换手率0.46%	流通股本20.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":57.52,"timestamp":1779912000000,"preClose":58.03,"halted":0,"volume":9348012,"hourTrading":{"tag":"盘前","latestPrice":57.75,"preClose":57.52,"latestTime":"04:32 EDT","volume":136,"amount":7866.529,"timestamp":1779957171115,"change":0.23,"changeRate":0.003999,"amplitude":0.006761},"delay":0,"changeRate":-0.00878855764259862,"floatShares":2031646263,"shares":2035753027,"eps":3.569767,"marketStatus":"盘前交易","change":-0.51,"latestTime":"05-28 05:19:36 EDT","open":58.03,"high":58.8,"low":57.1312,"amount":541195956.77076,"amplitude":0.028758,"askPrice":57.97,"askSize":100,"bidPrice":56.5,"bidSize":1,"shortable":3,"etf":0,"ttmEps":3.569767,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779975000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":57.52,"dividendRate":0.043482,"preHourTrading":{"tag":"盘前","latestPrice":57.75,"preClose":57.52,"latestTime":"04:32 EDT","volume":136,"amount":7866.529,"timestamp":1779957171115,"change":0.23,"changeRate":0.003999,"amplitude":0.006761},"postHourTrading":{"tag":"盘后","latestPrice":57.7,"preClose":57.52,"latestTime":"19:55 EDT","volume":683385,"amount":39308016.8958,"timestamp":1779926142987,"change":0.18,"changeRate":0.003129,"amplitude":0.003825},"volumeRatio":1.178859,"optionData":{"bulkOrders":[{"symbol":"BMY","call":false,"expireDate":1780632000000,"strike":"56.0","timestamp":1779901280237,"price":0.36,"volume":5000,"amount":180000,"type":"+"},{"symbol":"BMY","call":false,"expireDate":1780632000000,"strike":"57.0","timestamp":1779901280238,"price":0.59,"volume":2500,"amount":147500,"type":"+"}]},"impliedVol":0.2389,"impliedVolPercentile":0.024},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"1114324713","title":"施贵宝将于2026年ASCO®大会公布新数据，展示其肿瘤学产品组合与下一代管线的创新实力与广度","url":"https://stock-news.laohu8.com/highlight/detail?id=1114324713","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114324713?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:02","pubTimestamp":1779397351,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，将在2026年美国临床肿瘤学会（ASCO®）年会上公布一系列新的研究数据。这些数据将全面展示该公司在肿瘤学领域产品组合及下一代研发管线中科学创新的实力与广度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","LU0114720955.EUR","LU0868494617.USD","LU1670710661.SGD","LU1983299246.USD","BMY","BK4588","LU0882574055.USD","LU0237698245.USD","LU1291159041.SGD","LU1670710588.SGD","LU0096364046.USD","LU2133065610.SGD","LU1670711123.USD","LU0306806265.USD","LU1093756168.USD","LU1585245621.USD","LU2242652126.USD","IE0002141913.USD","LU0225284248.USD","LU0321505868.SGD","LU1430594728.SGD","LU1261432733.SGD","IE0009355771.USD","BK4007","LU1718418525.SGD","BK4585","LU1868837136.USD","IE00BFTCPJ56.SGD","LU1032466523.USD","LU2360032135.SGD","LU1074936037.SGD","LU1323610961.USD","IE00BFXG1179.USD","LU1868836914.USD","LU0225771236.USD","LU0306807586.USD","LU0456855351.SGD","LU0985481810.HKD","LU1868836591.USD","IE00BJJMRZ35.SGD","LU1868836757.USD","BK4581","LU0061475181.USD","LU2125154778.USD","LU1670711040.USD","LU1868837300.USD","LU2242646821.SGD","IE00BJT1NW94.SGD","LU1883839398.USD","LU1093756325.SGD","LU1571399168.USD","BK4532","IE00B2B36J28.USD","LU1989771016.USD","IE00BSNM7G36.USD","LU2125154935.USD","BK4559","LU0432979614.USD","BK4534","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636582564","title":"百时美施贵宝向3万名员工全面开放Anthropic公司Claude","url":"https://stock-news.laohu8.com/highlight/detail?id=2636582564","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636582564?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:41","pubTimestamp":1779288087,"startTime":"0","endTime":"0","summary":"　　生物制药巨头百时美施贵宝将为旗下超 3 万名员工接入Anthropic公司的Claude人工智能系统。　　生物制药巨头百时美施贵宝正式引入Anthropic旗舰级 AI 产品Claude，覆盖公司 3 万余名员工，全面深化人工智能与智能助手在药物研发、临床开发及企业日常办公等全场景的应用。　　对百时美施贵宝而言，本次携手Anthropic，是其多年来在集团内部全面落地人工智能战略的延续。","market":"us","thumbnail":"http://n.sinaimg.cn/finance/transform/116/w550h366/20260520/e94d-709299e92d02f68c312a32d4b4c7ff86.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/finance/transform/116/w550h366/20260520/e94d-709299e92d02f68c312a32d4b4c7ff86.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-20/doc-inhyqiyh6272009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU1093756325.SGD","BK4559","BK4532","LU1261432733.SGD","LU1291159041.SGD","LU1670711040.USD","LU2242652126.USD","IE0002141913.USD","LU0456855351.SGD","BK4588","LU1585245621.USD","LU0321505439.SGD","LU1883839398.USD","LU1670710588.SGD","BK4585","LU1032466523.USD","LU0868494617.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","LU0267386448.USD","LU1983299246.USD","LU0114720955.EUR","LU1670711123.USD","LU0882574055.USD","LU1868836757.USD","LU1323610961.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0306807586.USD","BK4534","LU2242646821.SGD","IE00BFXG1179.USD","LU2125154778.USD","LU0985481810.HKD","LU0096364046.USD","LU1670710661.SGD","LU0225284248.USD","LU0321505868.SGD","LU0306806265.USD","LU2125154935.USD","LU1430594728.SGD","LU0237698245.USD","LU1093756168.USD","LU0061475181.USD","LU1989771016.USD","BMY","LU0432979614.USD","LU1571399168.USD","BK4581","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636291840","title":"制药巨头集体拥抱AI智能体：百时美施贵宝(BMY.US)向3万员工推广Claude","url":"https://stock-news.laohu8.com/highlight/detail?id=2636291840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636291840?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:05","pubTimestamp":1779282310,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百时美施贵宝正在向其3万多名员工推广Anthropic的旗舰级Claude AI平台，以此扩大人工智能和AI智能体在研究、临床开发及企业运营中的应用。此外，百时美施贵宝表示，它正在使用Anthropic的编程工具Claude Code来加速其软件和AI的开发。该公司还表示，目前正在评估将Claude AI智能体应用于研究、药物开发以及商业和医学事务等领域。Anthropic的竞争对手OpenAI也已与该行业的关键领头羊达成了合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0985481810.HKD","LU0321505439.SGD","LU1074936037.SGD","LU2242646821.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU1868836914.USD","IE0009355771.USD","BK4532","IE00BFXG1179.USD","159819","BK1191","LU1670710661.SGD","LU1670711123.USD","LU2125154935.USD","LU0321505868.SGD","LU1868837300.USD","LU2360032135.SGD","LU0868494617.USD","LU0237698245.USD","BMY","LU1868836757.USD","IE0002141913.USD","LU1032466523.USD","LU1868836591.USD","BK4588","LU0114720955.EUR","LU1093756325.SGD","LU1430594728.SGD","LU2242652126.USD","LU2125154778.USD","01477","LU0061475181.USD","IE00B2B36J28.USD","BK4585","LU1323610961.USD","BK1574","LU0096364046.USD","LU0267386448.USD","BK4534","LU1261432733.SGD","LU0306807586.USD","LU0225284248.USD","LU0225771236.USD","LU1093756168.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU2133065610.SGD","LU1670710588.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147613870","title":"施贵宝与Anthropic达成战略协议，将Claude Enterprise确立为全球运营统一智能平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1147613870","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147613870?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:00","pubTimestamp":1779274829,"startTime":"0","endTime":"0","summary":"施贵宝已宣布与人工智能公司Anthropic达成一项战略协议，计划将Claude Enterprise作为其全球业务运营的统一智能平台。此举旨在通过先进的AI技术整合和优化公司全球范围内的业务流程与数据智能应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","LU0114720955.EUR","LU0868494617.USD","LU1670710661.SGD","LU1983299246.USD","BMY","BK4588","LU0882574055.USD","LU0237698245.USD","LU1291159041.SGD","LU1670710588.SGD","LU0096364046.USD","LU2133065610.SGD","LU1670711123.USD","LU0306806265.USD","LU1093756168.USD","LU1585245621.USD","LU2242652126.USD","IE0002141913.USD","LU0225284248.USD","LU0321505868.SGD","LU1430594728.SGD","LU1261432733.SGD","IE0009355771.USD","BK4007","LU1718418525.SGD","BK4585","LU1868837136.USD","IE00BFTCPJ56.SGD","LU1032466523.USD","LU2360032135.SGD","LU1074936037.SGD","LU1323610961.USD","IE00BFXG1179.USD","LU1868836914.USD","LU0225771236.USD","LU0306807586.USD","LU0456855351.SGD","LU0985481810.HKD","LU1868836591.USD","IE00BJJMRZ35.SGD","LU1868836757.USD","BK4581","LU0061475181.USD","LU2125154778.USD","LU1670711040.USD","LU1868837300.USD","LU2242646821.SGD","IE00BJT1NW94.SGD","LU1883839398.USD","LU1093756325.SGD","LU1571399168.USD","BK4532","IE00B2B36J28.USD","LU1989771016.USD","IE00BSNM7G36.USD","LU2125154935.USD","BK4559","LU0432979614.USD","BK4534","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111754724","title":"穆巴达拉投资公司申报持有施贵宝23.34万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1111754724","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111754724?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:21","pubTimestamp":1778854894,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的最新文件，阿布扎比主权财富基金穆巴达拉投资公司披露其持有美国制药巨头施贵宝的股份。申报文件显示，穆巴达拉目前持有施贵宝共计233,437股股票。作为全球领先的主权投资基金之一，穆巴达拉的投资动向常被视为市场风向标。施贵宝作为在肿瘤学、免疫学及心血管疾病领域拥有重磅产品的跨国药企，一直是机构投资者的核心配置标的之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c51812e8550b6fdc2a94c033e7f93915","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0868494617.USD","LU1093756325.SGD","BK4534","LU1585245621.USD","BK4588","LU1868836757.USD","LU0882574055.USD","LU1989771016.USD","LU0061475181.USD","LU0114720955.EUR","BMY","LU0985481810.HKD","BK4532","LU1670711040.USD","IE00BJT1NW94.SGD","LU2125154935.USD","LU1093756168.USD","LU0321505868.SGD","LU1430594728.SGD","LU0456855351.SGD","LU0321505439.SGD","LU2125154778.USD","LU1670710588.SGD","LU1261432733.SGD","LU0096364046.USD","LU0306806265.USD","IE0002141913.USD","LU0225771236.USD","LU2242652126.USD","LU2360032135.SGD","BK4581","LU1670710661.SGD","LU1983299246.USD","LU2242646821.SGD","LU1571399168.USD","IE00BSNM7G36.USD","LU1868836591.USD","LU1868837300.USD","LU1074936037.SGD","IE00BFXG1179.USD","LU0237698245.USD","BK4585","LU0432979614.USD","BK4559","LU1323610961.USD","LU1718418525.SGD","LU1670711123.USD","LU2133065610.SGD","LU0306807586.USD","LU1868836914.USD","LU1032466523.USD","LU1883839398.USD","IE00B2B36J28.USD","LU0267386448.USD","LU1291159041.SGD","LU1868837136.USD","BK4007","IE00BFTCPJ56.SGD","LU0225284248.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102515839","title":"Tempus AI扩大与施贵宝的战略合作，旨在提升肿瘤学和神经科学领域临床开发项目的成功率","url":"https://stock-news.laohu8.com/highlight/detail?id=1102515839","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102515839?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:31","pubTimestamp":1778761900,"startTime":"0","endTime":"0","summary":"Tempus AI正在深化与施贵宝的战略合作关系，此举旨在显著提高双方在肿瘤学及神经科学领域临床开发项目取得成功的可能性。此次合作扩展将进一步整合Tempus AI在人工智能与数据驱动洞察方面的专长，与施贵宝在药物研发领域的深厚经验相结合，共同致力于加速创新疗法的开发进程，并优化临床试验设计。通过强化数据共享与分析能力，双方期望能够更精准地识别潜在的治疗靶点，筛选出更可能受益的患者群体，从而提升整个药物研发管线的效率与成功率，为患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEM","BK4121","TEMT","BMY","LU1861558580.USD","BK4613","BK4611","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780599","title":"百时美施贵宝达成152亿美元中国药物交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780599","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635780599?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:18","pubTimestamp":1778678280,"startTime":"0","endTime":"0","summary":"百时美施贵宝已与江苏恒瑞医药签署了一项合作与许可协议，总金额最高可达152亿美元，使这家美国制药商能够获得一大批早期资产，借此利用中国在早期开发方面的效率。该协议涵盖肿瘤、血液学和免疫学领域的13个早期项目，百时美施贵宝将在2028年前向恒瑞支付高达9.5亿美元，其中包括6亿美元的预付款。该交易预计将于第三季度完成。这笔潜在交易的总规模表明，百时美施贵宝正对中国原研药物进行重大押注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-13/doc-inhxufva0656828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4534","LU0267386448.USD","LU0225284248.USD","LU0432979614.USD","LU1032466523.USD","LU1868836914.USD","IE00B2B36J28.USD","LU0061475181.USD","BK4588","LU1868837300.USD","LU0225771236.USD","BK4007","BK4532","LU2360032135.SGD","IE0002141913.USD","LU1868837136.USD","BK4559","LU1261432733.SGD","LU0114720955.EUR","LU1670710588.SGD","IE00BSNM7G36.USD","LU2242652126.USD","IE0009355771.USD","LU0985481810.HKD","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0321505868.SGD","LU0456855351.SGD","LU0306807586.USD","LU1323610961.USD","LU2125154778.USD","LU1868836591.USD","LU1883839398.USD","LU1670711040.USD","IE00BJT1NW94.SGD","LU0237698245.USD","LU1983299246.USD","IE00BFXG1179.USD","BMY","LU0882574055.USD","LU2125154935.USD","LU2133065610.SGD","LU0868494617.USD","BK4581","LU1989771016.USD","BK4585","IE00BFTCPJ56.SGD","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635320782","title":"携手推进肿瘤学、血液学及免疫学创新疗法 恒瑞医药与百时美施贵宝达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635320782","media":"经济参考网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635320782?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:20","pubTimestamp":1778664054,"startTime":"0","endTime":"0","summary":"5月12日，江苏恒瑞医药股份有限公司(简称“恒瑞医药”，600276.SH;01276.HK)与百时美施贵宝公司(简称“BMS”，NYSE：BMY)宣布达成全球战略合作及许可协议，共同推进13款涵盖肿瘤学、血液学及免疫学领域的早期创新项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735980065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023057109.AUD","BMY","LU2125154778.USD","LU0405327494.USD","01276","IE0009355771.USD","600276","BK0012","LU0225284248.USD","LU0306807586.USD","LU2495084118.USD","LU2242652126.USD","IE00BFXG1179.USD","LU1585245621.USD","LU0359201612.USD","LU0985481810.HKD","BK4007","LU0237698245.USD","LU1261432733.SGD","LU1868836591.USD","LU1868836757.USD","LU1146622755.USD","BK0183","LU1670710661.SGD","LU2580892862.HKD","LU1670711040.USD","LU1820825898.SGD","LU2328871848.SGD","LU1868837300.USD","LU1997245177.USD","BK0060","LU1064131003.USD","LU1093756168.USD","LU2242646821.SGD","LU0432979614.USD","LU0321505439.SGD","LU1571399168.USD","LU2097828474.EUR","LU2097828714.EUR","LU0225771236.USD","BK4532","LU0405327148.USD","LU2097828805.USD","LU2097828557.USD","LU1655091616.SGD","LU1670710588.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2543165471.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161668826","title":"Pacira Biosciences致信股东 重申其董事会提名人选的卓越资质","url":"https://stock-news.laohu8.com/highlight/detail?id=1161668826","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161668826?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:02","pubTimestamp":1778616151,"startTime":"0","endTime":"0","summary":"Pacira Biosciences已向股东致信，再次强调其提名的董事会成员具备卓越的专业资质与经验。\n此举旨在向投资者明确传达，公司推选的董事人选拥有引领公司未来发展的关键能力与深刻行业洞察。信中详细阐述了各位提名人的背景、技能及其能为公司带来的独特价值，以期在即将到来的董事会选举中获得股东的坚定支持。\n公司管理层相信，由这些经验丰富的专业人士组成的董事会，将能有效指导Pacira Biosciences的战略方向，持续为股东创造长期价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985481810.HKD","LU1291159041.SGD","IE0009355771.USD","LU1868836914.USD","LU1883839398.USD","LU0225771236.USD","LU2242646821.SGD","LU1074936037.SGD","LU1670710661.SGD","BK4534","LU0321505439.SGD","IE00B2B36J28.USD","LU1323610961.USD","IE00BFXG1179.USD","BMY","LU0432979614.USD","LU1868836591.USD","BK4581","LU1983299246.USD","IE00BFTCPJ56.SGD","LU1868837136.USD","LU2360032135.SGD","LU0225284248.USD","LU1868837300.USD","BK4007","LU0267386448.USD","LU1093756325.SGD","BK4585","BK4588","LU1430594728.SGD","LU0882574055.USD","LU0456855351.SGD","LU2125154778.USD","LU1670711040.USD","BK4532","IE00BJT1NW94.SGD","LU1670711123.USD","LU2242652126.USD","LU0306807586.USD","LU1032466523.USD","LU0306806265.USD","LU0114720955.EUR","LU0096364046.USD","LU1571399168.USD","LU1585245621.USD","LU2125154935.USD","LU0061475181.USD","PCRX","LU0321505868.SGD","IE00BSNM7G36.USD","LU1718418525.SGD","IE0002141913.USD","LU1093756168.USD","LU1670710588.SGD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU2133065610.SGD","BK4559","LU0868494617.USD","LU1868836757.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634126909","title":"港股异动 | 恒瑞医药(01276)最高涨超16%  与百时美施贵宝达成战略合作协议 潜在总交易额达152亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634126909","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634126909?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:35","pubTimestamp":1778564111,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)午后急升，最高涨超16%，截至发稿，涨6.21%，报70.15港元，成交额10.14亿港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260512/20260512133545_76516.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260512/20260512133545_76516.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","LU1074936037.SGD","LU0267386448.USD","LU0432979614.USD","LU1580142542.USD","LU1820825898.SGD","LU2328871848.SGD","LU1997245094.SGD","IE00B2B36J28.USD","LU0405327494.USD","BK0183","BK4581","LU1670710588.SGD","LU1655091616.SGD","LU2097828714.EUR","LU2242646821.SGD","600276","LU1868836757.USD","BK0060","LU2097828631.EUR","BK0028","VXUS","LU2242652126.USD","BK0188","LU0405327148.USD","LU0868494617.USD","LU1323610961.USD","LU1571399168.USD","LU2488822045.USD","IE0002141913.USD","LU1146622755.USD","LU0306807586.USD","LU1064131003.USD","01276","BK0012","LU1585245621.USD","LU0456855351.SGD","LU1032466523.USD","LU1430594728.SGD","BMY","LU1997245177.USD","LU1093756168.USD","LU1670711040.USD","LU1989771016.USD","LU1093756325.SGD","LU2148510915.USD","LU1983299246.USD","LU1969619763.USD","LU1868836591.USD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198821818","title":"恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1198821818","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198821818?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:03","pubTimestamp":1778562223,"startTime":"0","endTime":"0","summary":"5月12日，$恒瑞医药(01276)$午后直线拉升，一度涨超16%！该公司与BMS达成全球重磅合作，携手开发13款早期创新药。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","LU2580892789.USD","BK1161","LU0405327494.USD","LU2495084118.USD","LU2328871848.SGD","BK1574","BK0239","LU1064130708.USD","LU1655091616.SGD","600276","LU1820825898.SGD","LU2097828631.EUR","LU2097828714.EUR","LU1781817850.SGD","LU2148510915.USD","LU0359201612.USD","LU0359201885.HKD","LU2097828805.USD","BK0183","LU0359202008.SGD","BK0060","159992","LU1023057109.AUD","LU1328615791.USD","BK0028","BK0012","BMY","LU1255011170.USD","LU2289578879.USD","LU1997245177.USD","LU1997245094.SGD","01276","BK1191","LU2097828474.EUR","LU2097828557.USD","LU2543165471.USD","LU2580892862.HKD","LU0405327148.USD","BK0196","BK0188","LU1146622755.USD","LU1580142542.USD","LU1064131003.USD","LU2488822045.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1156948670","title":"恒瑞医药与施贵宝宣布战略合作，共同推进创新药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1156948670","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156948670?lang=zh_cn&edition=full","pubTime":"2026-05-12 12:39","pubTimestamp":1778560767,"startTime":"0","endTime":"0","summary":"恒瑞医药与施贵宝宣布达成战略合作协议，旨在共同推进肿瘤学、血液学及免疫学领域的创新药物研发。\n根据协议条款，施贵宝将向恒瑞医药支付最高达9.5亿美元的资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985481810.HKD","LU1291159041.SGD","IE0009355771.USD","LU1868836914.USD","LU1883839398.USD","LU0225771236.USD","LU2242646821.SGD","LU1074936037.SGD","LU1670710661.SGD","BK4534","LU0321505439.SGD","IE00B2B36J28.USD","LU1323610961.USD","IE00BFXG1179.USD","BMY","LU0432979614.USD","LU1868836591.USD","BK4581","LU1983299246.USD","IE00BFTCPJ56.SGD","LU1868837136.USD","LU2360032135.SGD","LU0225284248.USD","LU1868837300.USD","BK4007","LU0267386448.USD","LU1093756325.SGD","BK4585","BK4588","LU1430594728.SGD","LU0882574055.USD","LU0456855351.SGD","LU2125154778.USD","LU1670711040.USD","BK4532","IE00BJT1NW94.SGD","LU1670711123.USD","LU2242652126.USD","LU0306807586.USD","LU1032466523.USD","LU0306806265.USD","LU0114720955.EUR","LU0096364046.USD","LU1571399168.USD","LU1585245621.USD","LU2125154935.USD","LU0061475181.USD","LU0321505868.SGD","IE00BSNM7G36.USD","LU1718418525.SGD","IE0002141913.USD","LU1093756168.USD","LU1670710588.SGD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU2133065610.SGD","BK4559","LU0868494617.USD","LU1868836757.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634265332","title":"恒瑞医药(01276)与百时美施贵宝公司签署战略合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2634265332","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634265332?lang=zh_cn&edition=full","pubTime":"2026-05-12 12:18","pubTimestamp":1778559482,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，江苏恒瑞医药股份有限公司与百时美施贵宝公司达成全球战略合作及许可协议，共同推进 13 款涵盖肿瘤学、血液学及免疫学的早期项目，以加速创新药物研发，惠及全球患者。此次达成的协议与BMS及恒瑞的协同创新战略契合，彰显了双方在重大且未被满足医疗需求的领域，持续致力于通过合作推进科学创新。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B2B36J28.USD","LU2360032135.SGD","LU2488822045.USD","LU1997244956.HKD","LU2097828714.EUR","LU2495084118.USD","BK4532","LU1820825898.SGD","BK0183","01276","LU1781817850.SGD","LU2289578879.USD","LU1997245094.SGD","LU0321505439.SGD","LU1670711123.USD","LU0359201612.USD","LU2148510915.USD","IE00BJJMRZ35.SGD","BK0188","BK0060","LU1430594728.SGD","LU1323610961.USD","LU0882574055.USD","LU1074936037.SGD","LU2328871848.SGD","BK4559","LU1883839398.USD","LU1146622755.USD","LU0096364046.USD","LU0405327494.USD","LU2097828805.USD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0321505868.SGD","LU1093756325.SGD","LU1868836757.USD","BMY","LU0225771236.USD","600276","LU0456855351.SGD","IE0002141913.USD","LU2242646821.SGD","BK0028","BK4585","LU1868837136.USD","LU2125154778.USD","LU2097828557.USD","LU1093756168.USD","LU2543165471.USD","LU1032466523.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187547715","title":"恒瑞医药达成多项协议 加速推进肿瘤、血液及免疫领域13项早期研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1187547715","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187547715?lang=zh_cn&edition=full","pubTime":"2026-05-12 12:02","pubTimestamp":1778558542,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布达成一系列战略合作，旨在推动其旗下共计13个处于早期阶段的研发项目，这些项目主要聚焦于肿瘤学、血液病学及免疫学三大治疗领域。此举标志着该公司正通过外部合作，积极扩充并加速其创新药物管线的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU1146622755.USD","LU1255011170.USD","LU2125154778.USD","LU2148510915.USD","LU2328871848.SGD","LU0114720955.EUR","LU1571399168.USD","LU1580142542.USD","IE00BFTCPJ56.SGD","LU1868837300.USD","LU2133065610.SGD","IE00B2B36J28.USD","BK0183","BK4585","BK0028","LU0225284248.USD","BK0060","BK0188","BK4534","LU1430594728.SGD","LU2580892862.HKD","LU1781817850.SGD","LU1868837136.USD","BK1191","LU1023057109.AUD","BK0239","LU0306806265.USD","LU1670711123.USD","LU1718418525.SGD","LU1868836914.USD","LU2360032135.SGD","BK4581","LU2097828805.USD","LU0321505868.SGD","LU2242646821.SGD","LU1328615791.USD","BK0012","LU2495084118.USD","LU2242652126.USD","LU0405327148.USD","LU0237698245.USD","LU1670710661.SGD","IE0009355771.USD","LU1093756168.USD","LU1670710588.SGD","LU2097828557.USD","LU1868836591.USD","LU1868836757.USD","LU1989771016.USD","IE00BJT1NW94.SGD","LU1997244956.HKD","IE00BJJMRZ35.SGD","BK0196","LU0985481810.HKD","LU1997245177.USD","IE0002141913.USD","LU2125154935.USD","LU1585245621.USD","LU1093756325.SGD","LU0359201612.USD","LU2580892789.USD","LU1883839398.USD","BK4559","LU0359201885.HKD","LU0225771236.USD","BK4532","LU0432979614.USD","LU2097828474.EUR","LU1064130708.USD","LU0456855351.SGD","01276","LU1291159041.SGD","LU1064131003.USD","LU2097828631.EUR","LU0359202008.SGD","LU1969619763.USD","BMY","LU1261432733.SGD","LU0405327494.USD","LU0096364046.USD","LU1983299246.USD","LU2543165471.USD","LU1032466523.USD","LU1074936037.SGD","LU1655091616.SGD","BK4007","LU0321505439.SGD","LU2289578879.USD","LU0306807586.USD","LU0868494617.USD","LU0061475181.USD","LU0267386448.USD","LU1820825898.SGD","LU1997245094.SGD","LU1670711040.USD","LU2488822045.USD","LU0882574055.USD","IE00BSNM7G36.USD","LU2097828714.EUR","BK4588","LU1323610961.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171212027","title":"施贵宝Sotyktu获欧盟批准 用于治疗成人活动性银屑病关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1171212027","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171212027?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:07","pubTimestamp":1778238461,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其创新药物Sotyktu（deucravacitinib）已获得欧盟委员会批准，用于治疗成人活动性银屑病关节炎。该批准为患者提供了一种新的口服治疗选择。\nSotyktu是一种酪氨酸激酶2（TYK2）抑制剂，通过靶向特定的免疫通路发挥作用。此次获批基于多项临床研究数据，证实了该药物在改善疾病症状和体征方面的显著疗效。\n欧盟委员会的这项决定标志着Sotyktu在自身免疫疾病治疗领域取得重要进展。该药物此前已在美国获得用于斑块状银屑病的治疗许可，此次新适应症的获批进一步拓展了其临床应用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0868494617.USD","LU1093756325.SGD","BK4534","LU1585245621.USD","BK4588","LU1868836757.USD","LU0882574055.USD","LU1989771016.USD","LU0061475181.USD","LU0114720955.EUR","BMY","LU0985481810.HKD","BK4532","LU1670711040.USD","IE00BJT1NW94.SGD","LU2125154935.USD","LU1093756168.USD","LU0321505868.SGD","LU1430594728.SGD","LU0456855351.SGD","LU0321505439.SGD","LU2125154778.USD","LU1670710588.SGD","LU1261432733.SGD","LU0096364046.USD","LU0306806265.USD","IE0002141913.USD","LU0225771236.USD","LU2242652126.USD","LU2360032135.SGD","BK4581","LU1670710661.SGD","LU1983299246.USD","LU2242646821.SGD","LU1571399168.USD","IE00BSNM7G36.USD","LU1868836591.USD","LU1868837300.USD","LU1074936037.SGD","IE00BFXG1179.USD","LU0237698245.USD","BK4585","LU0432979614.USD","BK4559","LU1323610961.USD","LU1718418525.SGD","LU1670711123.USD","LU2133065610.SGD","LU0306807586.USD","LU1868836914.USD","LU1032466523.USD","LU1883839398.USD","IE00B2B36J28.USD","LU0267386448.USD","LU1291159041.SGD","LU1868837136.USD","BK4007","IE00BFTCPJ56.SGD","LU0225284248.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发，集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2026年第一季度，全球制药巨头的业绩版图再度刷新。　　有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道，已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BMY","LU0208291251.USD","IE00B2B36J28.USD","LU1066051498.USD","LU0265550946.USD","LU0203347892.USD","BK4516","SG9999001176.USD","IE00B4R5TH58.HKD","LU0106261372.USD","LU1699723380.USD","LU1934455277.USD","LU1934455194.USD","LU2023250843.SGD","BK4599","LU0648001328.SGD","LU2491050154.USD","SG9999014559.SGD","BK4550","LU1035773651.USD","BK4559","LU0859254822.USD","SG9999002232.USD","IE00BZ1G4Q59.USD","LU2360032135.SGD","LU2324357040.USD","LU0868494617.USD","NVS","LU1571399168.USD","NVOH","LU0289739699.SGD","LU1037948541.HKD","LU1941712264.USD","LU1989772840.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE000M9KFDE8.USD","LU0203345920.USD","LU2491049909.HKD","LU1116320737.USD","LU1974910355.USD","SG9999002224.SGD","SGXZ57979304.SGD","FXE","LU0861579265.USD","IE00BLSP4239.USD","LU0980610538.SGD","LU1066051811.HKD","LU1430594728.SGD","LU1989771016.USD","LU1057294990.SGD","LU2361044949.HKD","LU2357627491.SGD","LU0098860793.USD","LU0965509101.SGD","IE00BKVL7J92.USD","BK4533","LU1061106388.HKD","LU2089984988.USD","LU0965509010.AUD","LU0942090050.USD","IE00BLSP4452.SGD","LU0211331839.USD","NVO","IE0002141913.USD","LU2125154778.USD","BK4585","IE00B1BXHZ80.USD","SG9999001440.SGD","SG9999013999.USD","SG9999015358.SGD","LU0130102774.USD","SG9999014567.USD","IE00BJT1NW94.SGD","LU1066051225.USD","MRK","SG9999014542.SGD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0058720904.USD","LU1162221912.USD","LU0006306889.USD","LU1201861249.SGD","SG9999015341.SGD","LU0122379950.USD","LU0238689110.USD","LU2106854487.HKD","LU1116320901.HKD","LU2468319806.SGD","LU0234572021.USD","LU0130517989.USD","EURmain","LU0985320562.USD","LU0477156953.USD","LU0070302665.USD","LU2125154935.USD","LU2112291526.USD","LU2361044865.SGD","SG9999014575.USD","IE00BSNM7G36.USD","LU1037948897.HKD","LU1929549753.HKD","LU0432979614.USD","LU2461242641.AUD","LU0266013472.USD","LU1941712348.USD","LU1069347547.HKD","LU1917777945.USD","LU1023059063.AUD","LU1934455863.HKD","BK4588","LU0868494708.USD","IE0009355771.USD","EUO","LLY","LU0265550359.USD","LU2023250504.SGD","IE00BBT3K403.USD","LU2491050071.SGD","BK4007","MEURmain","SG9999001176.SGD","AZN","SNY","NVOX","LU1585245621.USD","BK4532","LU2361045086.USD","LU1291159041.SGD","LU1093756168.USD","LU0965509283.SGD","LU0154236417.USD","BK4534","IE00BN8TJ469.HKD","LU0320765489.SGD","LU0965508806.USD","LU0320765646.SGD","LU1989772923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144973551","title":"异动解读 | 施贵宝盘中大涨5.09%，季度利润超预期且重申积极业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1144973551","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144973551?lang=zh_cn&edition=full","pubTime":"2026-05-01 03:54","pubTimestamp":1777578891,"startTime":"0","endTime":"0","summary":"施贵宝（BMY）今日盘中大涨5.09%，引起了市场的广泛关注。消息面上，公司公布的季度利润超出华尔街预期，主要得益于抗凝血药艾乐妥（Eliquis）及新型抗癌药物的销售表现强劲。同时，公司重申了2026年财务业绩指引，并预计实际业绩将趋向预期区间的上限，这增强了投资者对公司盈利能力的信心。此外，公司高管在电话会议中强调，业务发展是资本配置的首要任务，并指出公司拥有充足的财务灵活性以寻求战略并购机会，进一步支撑了市场对其长期增长前景的乐观情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182260895","title":"施贵宝高管重申业务发展仍为资本配置首要任务 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1182260895","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182260895?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:30","pubTimestamp":1777552212,"startTime":"0","endTime":"0","summary":"在最新电话会议中，施贵宝公司高管强调，业务发展将继续作为公司资本配置的最高优先级。这一表态凸显了该制药巨头通过战略性投资驱动长期增长的坚定承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0985481810.HKD","BK4532","LU2125154778.USD","LU0225771236.USD","LU1571399168.USD","LU2242652126.USD","IE0009355771.USD","LU0868494617.USD","LU2360032135.SGD","LU0321505868.SGD","LU1670710661.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","BMY","LU0061475181.USD","LU1291159041.SGD","LU1983299246.USD","IE0002141913.USD","LU1093756168.USD","IE00BFXG1179.USD","LU1430594728.SGD","LU2133065610.SGD","LU1670711123.USD","LU0882574055.USD","LU1032466523.USD","LU1261432733.SGD","IE00BSNM7G36.USD","LU1074936037.SGD","LU1585245621.USD","LU1868836914.USD","LU1868837300.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU1670710588.SGD","IE00B2B36J28.USD","LU0237698245.USD","LU1868836591.USD","LU1989771016.USD","BK4588","LU1670711040.USD","LU0321505439.SGD","BK4585","LU0267386448.USD","LU0114720955.EUR","LU0432979614.USD","LU0456855351.SGD","LU0306807586.USD","LU1883839398.USD","LU2125154935.USD","LU1718418525.SGD","LU0096364046.USD","BK4559","LU0306806265.USD","LU0225284248.USD","LU1868837136.USD","BK4007","LU1868836757.USD","BK4534","BK4581","LU2242646821.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111101960","title":"施贵宝重申2026财年指引：总营收与调整后每股收益预计将达区间高端","url":"https://stock-news.laohu8.com/highlight/detail?id=1111101960","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111101960?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:59","pubTimestamp":1777546764,"startTime":"0","endTime":"0","summary":"制药巨头施贵宝(Bristol-Myers Squibb)近日重申了其2026年度的财务业绩指引。公司表示，目前各项运营指标显示，全年总营收和调整后每股收益均有望达到此前预期范围的上限水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BMY","LU0267386448.USD","LU2125154778.USD","LU2133065610.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0225284248.USD","LU1868836914.USD","LU0306807586.USD","IE00BSNM7G36.USD","LU1868837136.USD","LU0321505868.SGD","LU2242652126.USD","IE00BFXG1179.USD","LU1585245621.USD","LU0456855351.SGD","LU0985481810.HKD","BK4007","LU0237698245.USD","LU1261432733.SGD","LU1868836591.USD","BK4585","LU1868836757.USD","LU0868494617.USD","LU1323610961.USD","LU1670710661.SGD","LU0114720955.EUR","LU0096364046.USD","LU1670711040.USD","BK4588","LU2125154935.USD","LU1868837300.USD","LU1983299246.USD","IE0002141913.USD","LU0306806265.USD","LU1093756168.USD","LU1989771016.USD","BK4559","LU0061475181.USD","LU0321505439.SGD","LU0432979614.USD","LU1571399168.USD","LU2242646821.SGD","LU1032466523.USD","BK4532","LU0225771236.USD","LU1718418525.SGD","LU1883839398.USD","LU1430594728.SGD","LU1074936037.SGD","LU1670711123.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU2360032135.SGD","LU1291159041.SGD","IE00B2B36J28.USD","BK4534","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537129","title":"上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631537129?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:04","pubTimestamp":1777417480,"startTime":"0","endTime":"0","summary":"丨2026年4月29日星期三丨NO.1泰格医药一季度净利润同比减少70.36%4月28日，泰格医药发布2026年一季报，公司实现营业收入18.01亿元，同比增加15.17%；实现归属于上市公司股东的净利润4904.31万元，同比减少70.36%；实现归属于上市公司股东的扣除非经常性损益的净利润1.20亿元，同比增加17.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293723254882.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293723254882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","02607","601607","159938","BMY","301015"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":-0.0045},{"period":"3month","weight":-0.0586},{"period":"6month","weight":0.1691},{"period":"1year","weight":0.2267},{"period":"ytd","weight":0.0664}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.007963},{"month":4,"riseRate":0.468085,"avgChangeRate":-0.005808},{"month":5,"riseRate":0.553191,"avgChangeRate":0.001512},{"month":6,"riseRate":0.608696,"avgChangeRate":0.009417},{"month":7,"riseRate":0.413043,"avgChangeRate":-0.001733},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.001022},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}